Contact us

Our latest news

Back to news >

Fanny Joubert Joins the Seda Team as Senior Scientist

We are pleased to announce our latest appointment to the Seda team, Fanny Joubert, who joins us as Senior Scientist. Fanny has extensive technical experience in Nanotechnology and more particularly in the development of delivery systems for small molecules and nucleic acid therapeutics. After gaining a bachelor’s degree in Science and Technology at the University of Bordeaux 1, followed by an engineering diploma in Materials Science at Polytech’ Montpellier, France, Fanny then undertook a PhD in Polymer Chemistry at Durham University and has worked as a Research Associate for 6+ years within both academic and large pharma organisations.

Her specialist background includes a range of respected synthetic polymer chemistry applications where she has developed key skills in nanomaterials such as nanoparticles, nanosponges and hydrogels. Fanny has worked on a range of projects including nanomedicinal formulations for pancreatic cancer and development of drug delivery platforms. Her expertise includes chemical derivatisations, monomer and polymer syntheses and she has a range of experience focussing on polymers for healthcare and precision nanomedicine applications.

Here at Seda her current focus is to support clients in their development of complex medicines using her deep understanding of Nanotechnology manufacture and characterisation. We have direct experience of taking several nanomedicine and other complex delivery systems from preclinical to clinical development. We have established a network of experts in the diverse array of advanced characterisation techniques that are so vital to success in this field. In addition, we can leverage in-house modelling and simulation expertise to guide the development and selection of formulation candidates for optimal in vivo performance. Our in-house DMPK and Clinical Pharmacology capability, together with close alliances to other non-clinical and clinical experts are ideal for ensuring the seamless communication required to maximise success of complex medicines, where minor changes in formulation or manufacturing process can have major impact on biodistribution (and hence safety/efficacy).

Please join us in welcoming Fanny to the team.